指南与共识骨软组织肉瘤与黑色素瘤

颅外横纹肌样瘤:法国儿童肿瘤学会(SFCE)系列患者按欧洲儿童软组织肉瘤研究组推荐采用剂量压缩策略治疗的结果

Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tisue sarcoma Study Group recommendations.
指南 / 共识 · Eur J Cancer · 2021-12-18

本研究回顾性分析法国35例接受欧洲儿童软组织肉瘤研究组2014年剂量压缩方案(VDCy/IE每2周)治疗的颅外恶性横纹肌样瘤患儿,中位随访50.4个月,2年总生存率47.6%、无事件生存率42.9%,局部病变与完全切除与良好结局显著相关,未完全切除及转移/多灶患者预后仍差。

要点

  • 35例患儿接受VDCy/IE每2周密集化疗,实际递送理论累积剂量的87-97%,耐受性良好。
  • 2年总生存率47.6%(95%CI 30.2-63.1),无事件生存率42.9%(95%CI 26.5-58.3)。
  • 单因素分析中局部病变与完全切除与良好结局显著相关。

核心结论

  • VDCy/IE密集剂量化疗短期毒性不显著,包括婴儿;但未完全切除及转移或多灶患者结局仍差,作者认为这些患者可分层为高危组,需要新的即刻治疗策略如靶向药物联合多模式治疗。

研究设计与样本

  • 回顾性研究,纳入2019年1月前在法国按欧洲儿童软组织肉瘤研究组2014年新推荐治疗的儿童,共35例。

主要发现

  • 原发肿瘤位于软组织18例、肾脏11例、肝脏6例;诊断中位年龄17.5个月(范围1.2-198.2)。
  • 诊断时37.1%存在远处病变(转移或同时性肿瘤);17.1%患者检出SMARCB1胚系致病性变异。
  • 化疗耐受性总体良好,实际递送理论累积剂量的87-97%;两疗程中位间隔18天。
  • 83%患者行手术切除(R0 19例、R1 7例、R2 3例),49%患者接受局部放疗。
  • 中位随访50.4个月(范围16.5-134.1),2年总生存率47.6%(95%CI 30.2-63.1),2年无事件生存率42.9%(95%CI 26.5-58.3)。

关键数值与推荐

  • 欧洲儿童软组织肉瘤研究组2014年推荐:VDCy(长春新碱-多柔比星-环磷酰胺)与IE(异环磷酰胺-依托泊苷)密集化疗每2周,联合早期手术及肿瘤部位放疗。

临床怎么用

  • 作者认为未完全切除及转移或多灶患者可分层为高危组,需要新的即刻治疗策略如靶向药物联合多模式治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Extracranial malignant rhabdoid tumours are tumours that mainly affect young children and have a poor prognosis. In 2014, the European Paediatric Soft-tissue sarcoma Study Group developed treatment recommendations consisting in intensive dose chemotherapy every 2 weeks using vincristine-doxorubicin-cyclophosphamide (VDCy) and ifosfamide-etoposide (IE) associated with early surgery and irradiation of tumour sites. METHODS: A retrospective study was conducted on children treated in France by these new recommendations up to January 2019. RESULTS: Thirty-five patients were identified. The primary tumour was in miscellaneous soft parts for 18 patients, in the kidney for 11 and in the liver for six. The median age at diagnosis was 17.5 months (range 1.2-198.2). Distant locations (metastatic or synchronous tumours) were present in 37.1% at diagnosis. SMARCB1 germline pathogenic variant was detected in 17.1% of patients. Overall tolerance was good, with 87-97% of theoretical chemotherapy cumulative doses actually delivered. The median interval between two courses was 18 days. Surgical resection was performed in 83% (19 R0, 7 R1 and 3 R2) and local radiotherapy in 49% of patients. After a median follow-up of 50.4 months (range 16.5-134.1), the 2-year overall and event-free survivals were 47.6% (95% confidence interval [CI] 30.2-63.1) and 42.9% (95% [CI] 26.5-58.3), respectively. On univariate analyses, localised disease and gross total resection were significantly associated with favourable outcomes. CONCLUSIONS: Intensive dose chemotherapy with VDCy/IE can be administrated with no remarkable short-term toxicity, including in infants. However, the outcome remains poor for patients without gross total resection and with metastatic or multifocal disease. These patients could be stratified into a high-risk group that requires a new immediate therapeutic approach such as targeted agents combined with multimodal therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Enault M, Minard-Colin V, Corradini N, et al. Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tisue sarcoma Study Group recommendations. Eur J Cancer. 2021. PMID: 34929472. doi:10.1016/j.ejca.2021.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。